[
  {
    "text": "JOSH KRIEGER: Many of the\ngreat advances in human health",
    "start": "0",
    "end": "2333"
  },
  {
    "text": "have been due to\ncutting edge drugs.",
    "start": "2333",
    "end": "3989"
  },
  {
    "text": "These innovations require not\nonly great scientific vision,",
    "start": "3990",
    "end": "7080"
  },
  {
    "text": "but a willingness to take on\ngreat technical and commercial",
    "start": "7080",
    "end": "10080"
  },
  {
    "text": "uncertainty.",
    "start": "10080",
    "end": "10769"
  },
  {
    "text": "Generating the next\nbreakthrough therapies",
    "start": "10770",
    "end": "12690"
  },
  {
    "text": "depends on drug developers'\nability to identify and fund",
    "start": "12690",
    "end": "16078"
  },
  {
    "text": "high impact R&D.",
    "start": "16079",
    "end": "17460"
  },
  {
    "text": "While many organizations\nwant to pursue",
    "start": "17460",
    "end": "19349"
  },
  {
    "text": "these transformational projects,\nrisk aversion, career concerns,",
    "start": "19350",
    "end": "22830"
  },
  {
    "text": "and scientific norms often\nsteer firms towards more",
    "start": "22830",
    "end": "25650"
  },
  {
    "text": "incremental innovation.",
    "start": "25650",
    "end": "26730"
  },
  {
    "text": "And in collaboration with\nNovartis' Genesis Labs program,",
    "start": "26730",
    "end": "29730"
  },
  {
    "text": "we've been studying the\nevaluation of early stage",
    "start": "29730",
    "end": "32220"
  },
  {
    "text": "ideas.",
    "start": "32220",
    "end": "32910"
  },
  {
    "text": "How do scoring processes\ninfluence the types of projects",
    "start": "32910",
    "end": "35989"
  },
  {
    "text": "that enter the pipeline?",
    "start": "35990",
    "end": "36990"
  },
  {
    "text": "We find that\nscientist evaluators",
    "start": "36990",
    "end": "38790"
  },
  {
    "text": "show a bias for safer projects\neven when the company looks",
    "start": "38790",
    "end": "41940"
  },
  {
    "text": "to be more daring.",
    "start": "41940",
    "end": "43020"
  },
  {
    "text": "We also find that evaluators are\nquite sensitive to their peers",
    "start": "43020",
    "end": "45900"
  },
  {
    "text": "funding preferences.",
    "start": "45900",
    "end": "46980"
  },
  {
    "text": "If we want lifesaving\ntreatments in the clinic,",
    "start": "46980",
    "end": "49208"
  },
  {
    "text": "we have to learn how\nto match the decisions",
    "start": "49208",
    "end": "51000"
  },
  {
    "text": "at the start of the R&D\npipeline to the therapies we",
    "start": "51000",
    "end": "53760"
  },
  {
    "text": "want for ourselves and\nfor our loved ones.",
    "start": "53760",
    "end": "56070"
  },
  {
    "text": "[MUSIC PLAYING]",
    "start": "56070",
    "end": "58500"
  }
]